sustained loss neoplastic phenotype brief inactivation myc
pharmacological inactivation oncogenes investigated possible therapeutic strategy cancer one potential drawback cessation therapy may allow reactivation oncogene tumor regrowth used conditional transgenic mouse model myc-induced tumorigenesis demonstrate brief inactivation myc results sustained regression tumors differentiation osteogenic sarcoma cells mature osteocytes subsequent reactivation myc restore cells malignant properties instead induced apoptosis thus brief myc inactivation appears cause epigenetic changes tumor cells render insensitive myc-induced tumorigenesis results raise possibility transient inactivation myc may effective therapy certain cancers
